Expression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies

J Drugs Dermatol. 2024 Apr 1;23(4):e118-e119. doi: 10.36849/JDD.7941.

Abstract

Interleukin (IL)-4-targeted therapies have revolutionized management of inflammatory dermatoses.

Publication types

  • Editorial

MeSH terms

  • Biological Products*
  • Biological Therapy
  • Humans
  • Interleukin-4
  • Neoplasms* / drug therapy
  • Psoriasis* / therapy

Substances

  • Interleukin-4
  • Biological Products